甲磺酸伊马替尼与17-AAG在过表达BCR-ABL的伊马替尼耐药细胞中的交叉耐药性。 - Suppr

Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.

作者信息

Topaly Julian, Schad Moritz, Laufs Stephanie, Melo Junia V, Zeller W Jens, Fruehauf Stefan

出版信息

Br J Haematol. 2003 May;121(4):672-3. doi: 10.1046/j.1365-2141.2003.04330.x.

DOI:10.1046/j.1365-2141.2003.04330.x

PMID:12752112

Abstract

摘要

相似文献

Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.

Br J Haematol. 2003 May;121(4):672-3. doi: 10.1046/j.1365-2141.2003.04330.x.

Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.

Cancer Res. 2002 Oct 15;62(20):5761-9.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47. doi: 10.1158/1078-0432.CCR-05-2282.

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.

Pediatr Res. 2005 Mar;57(3):430-7. doi: 10.1203/01.PDR.0000153871.45184.19. Epub 2005 Jan 19.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

Blood. 2005 Feb 15;105(4):1768-76. doi: 10.1182/blood-2004-09-3413. Epub 2004 Oct 28.

Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.

Leuk Lymphoma. 2004 Feb;45(2):237-45. doi: 10.1080/1042819031000151905.

Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.

Biochim Biophys Acta. 2010 Oct;1804(10):1974-87. doi: 10.1016/j.bbapap.2010.04.009. Epub 2010 Apr 24.

Chronic myeloid leukemia. Sceptical scientists.

Lancet. 2001 Dec;358 Suppl:S11. doi: 10.1016/s0140-6736(01)07024-6.

STI571 (Gleevec) as a paradigm for cancer therapy.

Trends Mol Med. 2002;8(4 Suppl):S14-8. doi: 10.1016/s1471-4914(02)02305-5.

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Cancer Res. 2004 Jan 15;64(2):672-7. doi: 10.1158/0008-5472.can-03-1484.

引用本文的文献

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Int J Hematol. 2004 Jun;79(5):420-33. doi: 10.1532/ijh97.04032.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献